BAVARIAN NORDIC
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1992-01-01
- Employees
- 759
- Market Cap
- $3.1B
A Phase 3 Trial of the CHIKV VLP Vaccine in Children
- Conditions
- Chikungunya Virus
- Interventions
- Biological: CHIKV VLP vaccineBiological: Placebo
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 720
- Registration Number
- NCT07003984
- Locations
- 🇺🇸
Velocity Clinical Research-Omaha, Omaha, Nebraska, United States
🇺🇸Velocity Clinical Research - Salt Lake City, West Jordan, Utah, United States
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 400
- Registration Number
- NCT06899802
- Locations
- 🇺🇸
Benchmark Research, San Angelo, Texas, United States
🇺🇸Lifeline Primary Care, Inc. / CCT Research, Lilburn, Georgia, United States
🇺🇸Johnson County Clin-Trials, Lenexa, Kansas, United States
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 460
- Registration Number
- NCT06549530
- Locations
- 🇨🇩
University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the
🇺🇬Uganda Virus Research Institute, Entebbe, Uganda
🇺🇬Epicentre Mbarara Research Centre, Mbarara, Uganda
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
- Conditions
- Chikungunya Virus Infection
- Interventions
- Biological: CHIKV VLP vaccine boosterBiological: Placebo booster
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 800
- Registration Number
- NCT06007183
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States
🇺🇸Optimal Research, LLC, Peoria, Illinois, United States
🇺🇸Suncoast Research Associates, LLC, Miami, Florida, United States
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
- Conditions
- Chikungunya Virus
- Interventions
- Biological: PlaceboBiological: CHIKV VLP/adjuvant
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 413
- Registration Number
- NCT05349617
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Suncoast Research Associates, LLC, Miami, Florida, United States
🇺🇸Global Clinical Research Professionals (GCP), Saint Petersburg, Florida, United States
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 4205
- Registration Number
- NCT05329220
- Locations
- 🇺🇸
Achieve Clinical Research LLC d/b/a Accel Research Sites, Birmingham, Alabama, United States
🇺🇸Arizona Clinical Trials, Mesa, Arizona, United States
🇺🇸Tucson Neuroscience Research - M3 WR, Tucson, Arizona, United States
MVA-BN-RSV Vaccine Trial
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: MVA-BN-RSV vaccine
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 20419
- Registration Number
- NCT05238025
- Locations
- 🇺🇸
North Alabama Research Center, LLC, Athens, Alabama, United States
🇺🇸Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Achieve Clinical Research, LLC d/b/a Accel Research Sites, Birmingham, Alabama, United States
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
- Conditions
- COVID-19 Disease
- Interventions
- Biological: ABNCoV2 100ugBiological: ABNCoV2 50ug
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 197
- Registration Number
- NCT05077267
- Locations
- 🇩🇪
Emovis GmbH, Berlin, Germany
🇩🇪Velocity Clinical Research Hamburg, Hamburg, Germany
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317
- Conditions
- Chikungunya Virus
- Interventions
- Biological: CHIKV VLP/adjuvantBiological: Placebo
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 3258
- Registration Number
- NCT05072080
- Locations
- 🇺🇸
Optimal Research, LLC, Rockville, Maryland, United States
🇺🇸Alliance for Multispecialty Research - Mobile, Mobile, Alabama, United States
🇺🇸Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
- Conditions
- Chikungunya Virus
- Interventions
- Biological: CHIKV VLP, adjuvanted
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 25
- Registration Number
- NCT05065983
- Locations
- 🇺🇸
Johnson County ClinTrials, Lenexa, Kansas, United States